CGNX stock up 3.85% intraday: Cognex (CGNX) NASDAQ $44.00 10 Feb 2026 ahead of earnings

CGNX stock jumped 3.85% intraday to $44.00 on 10 Feb 2026 in NASDAQ trading after volume picked up to 901,414 shares. The move comes one day before Cognex Corporation reports results, creating an earnings-driven squeeze for short-term traders. We examine the drivers behind the rise, the company’s valuation metrics such as PE 67.26 and EPS $0.65, and what traders should watch in the AI and machine-vision sector before the earnings print.

Intraday price action and market context

Shares of Cognex Corporation (CGNX) on NASDAQ traded between $43.42 and $44.23 today, closing near $44.00 on elevated flow. Volume of 901,414 compares with an average of 1,813,177, giving a relative volume of 1.39 and signaling above-normal interest ahead of the earnings event.

Earnings catalyst and analyst signals

Cognex reports earnings on 11 Feb 2026, which investors are treating as the key trigger. Wall Street coverage ranges from a consensus price target near $45.64 to individual targets that span $38.00 to $58.00, reflecting mixed views on near-term demand for machine-vision hardware and AI software.

Analyst sentiment shows 5 Buys and 2 Holds in recent tallies, producing a neutral consensus score. Institutional buying was noted in recent filings, including a boost from Oppenheimer Asset Management.

Fundamentals, valuation and sector placement

Cognex operates in Technology, industry Hardware, Equipment & Parts, with a market cap of $7.33B in the United States market. Key ratios: PE 67.26, price/sales 7.55, price/book 4.93, and current ratio 3.96, showing strong liquidity but premium valuation versus peers.

Revenue per share is 5.79, free cash flow per share is 1.27, and payout ratio is 49.16%, indicating steady cash generation but limited yield with dividend per share $0.325.

Technical setup and trading signals for AI stocks

Short-term technicals favor momentum: RSI 59.29, ADX 25.84, ATR 1.09, and Bollinger middle band near $36.79. The stock is above its 50-day average $38.32 and 200-day average $37.83, which supports a bullish near-term bias.

Traders should watch increased implied volatility around the earnings date and the stock’s ability to hold intraday support near $43.40 on any pullback.

Meyka AI rating and model forecast

Meyka AI rates CGNX with a score out of 100: 71.91 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not investment advice.

Meyka AI’s forecast model projects a quarterly price of $36.81, a monthly level at $31.69, and a yearly figure of $30.64. Versus the current price $44.00, the model implies downside of -16.34% (quarterly) and -30.37% (yearly). Forecasts are model-based projections and not guarantees.

Final Thoughts

Key takeaways on CGNX stock: intraday strength to $44.00 on 10 Feb 2026 reflects positioning ahead of Cognex Corporation’s earnings report and continued interest in AI-driven machine vision. The company shows solid liquidity with a current ratio 3.96 and free cash flow per share $1.27, but valuation is rich at PE 67.26 and price/sales 7.55. Analyst coverage is mixed, with a consensus price target near $45.64, while Meyka AI’s model projects lower levels over the quarter and year, implying downside of -16.34% (quarter) and -30.37% (year) from $44.00. For AI stock strategies, the trade-off is clear: exposure to long-term growth in machine vision versus near-term earnings and valuation risk. We recommend watching tomorrow’s results, order flow, and updates to guidance. Meyka AI’s real-time tools and model-based analysis can help monitor reactions and update price targets as new data arrives. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.